

Connecting epithelial polarity, proliferation and cancer in *Drosophila*: the many faces of *lgl* loss of function

DANIELA GRIFONI*, FRANCESCA FROLDI# and ANNALISA PESSION

Dipartimento di Farmacia e Biotecnologie, University of Bologna, Italy

ABSTRACT Loss of cell polarity is a prominent feature of epithelial cancers. Several tumour-suppressor genes are indeed involved in establishing and maintaining a correct apical-basal polarity suggesting that a link exists between disruption of epithelial polarity and the control of cell proliferation. Nevertheless, the molecular basis of this link is only beginning to be unveiled. In *Drosophila*, the tumour suppressor gene *lethal giant larvae (lgl)* is widely used as a genetic tool in cancer modelling: its loss of function causes neoplastic growth of the imaginal tissues, larval epithelial organs from which adult structures originate. These mutant epithelia are characterised by loss of cell polarity and tissue architecture as well as hyperproliferation. We observed that in a clonal context, the ability of *lgl* mutant cells to express their neoplastic potential correlates with the levels of the oncoprotein *Myc*, a master regulator of cell growth and proliferation. Malignant, polarity-deficient mutant cells upregulate *Myc* and are able to overcome the tumour-suppressive defences imposed by the surrounding wild-type tissue. How does the loss of *lgl* function induce an increase in *Myc* levels? The answer to this question came from the finding that *Lgl* is an upstream regulator of the Hippo pathway, a highly conserved signalling network that controls proliferation of epithelial cells and organ size. The core of this pathway responds to several upstream regulators and converges on the inhibition of a transcriptional co-factor, *Yorkie*, which, as we and others have shown, is a direct regulator of the *myc* promoter. In this review we discuss the key findings that contributed to the identification of this regulatory network that links cell polarity to cell proliferation control.

KEY WORDS: *Drosophila*, cell competition, *Myc*, *Lgl*, cancer

Introduction

The knowledge of the genetic basis of cancer is the groundwork on which researchers can build and verify their experimental hypotheses, hopefully leading to effective medical treatments. Cellular and animal models have deeply contributed to the acquisition of this knowledge, and the fruitfly *Drosophila melanogaster* has been recently used to investigate the genetic mechanisms underlying the behaviour of cancer cells growing in heterotypic backgrounds. Differently from what happens to mutant cells bearing a genetic arrangement identical to their neighbours, which behave in a stereotypical manner, the same cells growing in heterotypic contexts can indeed show diametrically opposite behaviours, from being eliminated from the tissue to growing faster and faster, overwhelming the adjacent populations. Such kind of genetic analysis, which is to date the most accurate way to model human tumourigenesis,

accounts on the possibility in *Drosophila* tissues to generate single mutant cells which, while proliferating, are influenced by different chemical and physical stimuli depending on the surrounding microenvironment. To this purpose, mutations in tumour suppressor genes have been extensively used to induce cancer in different genetic contexts, and here we summarise recent advances in the field obtained from the study of *lgl* function in tumour biology.

lgl and cancer

lethal (2) giant larvae was the first tumour suppressor described in literature (Gateff, 1978). It is classified as neoplastic tumour

Abbreviations used in this paper: aPKC, atypical protein kinase C; dlG, discs large; Hpo, hippo; JNK, c-jun N-terminal kinase; *lgl*, lethal giant larvae; scrib, scribble; Yki, yorkie.

*Address correspondence to: Daniela Grifoni, University of Bologna, Dipartimento di Farmacia e Biotecnologie, Via Selmi 3, 40126 Bologna, Italy.
Tel: +39(0)51-209-4179. Fax: +39(0)51-209-4286. E-mail: daniela.grifoni@unibo.it - web: <http://www.unibo.it/Faculty/default.htm?UPN=daniela.grifoni%40unibo.it>

#Present address: Peter MacCallum Cancer Centre, Melbourne, Australia

Accepted: 6 November 2013. Final, author-corrected PDF published online: 9 December 2013.

suppressor gene (nTSG) as its loss of function (LOF) causes malignant growth of *Drosophila* ectodermal derivatives: imaginal discs (larval epithelial structures which originate adult organs during metamorphosis) and the neuroblasts of the larval brain. As a result of *lgl* mutation, these organs undergo loss of apical-basal (A/B) cell polarity and excessive proliferation, leading to severe alterations in tissue organisation. Mutant cells are unable to exit cell cycle and never differentiate, forming amorphous masses that lead to an extended larval period and pre-pupal lethality (Bilder, 2004). These tumorous masses are invasive, as they produce basement membrane-degrading enzymes, fuse with adjacent organs and become highly metastatic upon transplantation in adult naive hosts (Woodhouse *et al.*, 1998; Beaucher *et al.*, 2007a, Beaucher *et al.*, 2007b).

Given the strong similarities between *lgl* tissues and human epithelial cancers, and the high degree of functional conservation (see below), *lgl* mutants have been extensively used as genetic tools for the investigation of the molecular basis of epithelial transformation (Froldi *et al.*, 2008). The human genome encodes two *Drosophila* Lgl protein orthologues: Lgl-1 and Lgl-2 (also known as Hugel-1 and Hugel-2); several lines of evidence showing decreased expression or loss of Lgl-1/2 in primary human tumours seem to indicate that they play a role in mammalian tumorigenesis. Indeed we and others showed that *Lgl-1* transcript results decreased or completely absent in a variety of human epithelial malignancies such as breast, lung, prostate, ovarian cancers and melanoma (Grifoni *et al.*, 2004; Kuphal *et al.*, 2006). *Lgl-1* loss has also been implicated in colorectal cancer progression, where it was found to be associated with advanced stages and lymph node metastases (Schimanski *et al.*, 2005); it is also correlated to reduced survival in glioblastoma (Korshunov *et al.*, 2006), where its inactivation has been recently shown to be responsible for the maintenance of a population of undifferentiated cells named *tumour initiating cells* (Gont *et al.*, 2013). Finally, the occurrence of aberrant splicing variants has been associated with hepatocellular carcinoma progression (Lu *et al.*, 2009). This evidence strongly indicates that *lgl* human orthologues also function as tumour suppressor genes.

***lgl* and cell polarity**

The plasma membrane of epithelial cells is subdivided into two functionally distinct domains, apical and baso-lateral domains, by means of epithelial cell junctions and protein complexes. The lateral domain interconnects neighbouring cells, while the apical domain forms a specialised surface usually not in permanent contact with other cells. This distinct polarisation along the apical-basal axis is essential for adhesion, communication, vectorial transport, permeability and morphogenetic properties of epithelia (Dow and Humbert, 2007) and its alteration is a hallmark of epithelial cancers (Wodartz and Näthke, 2007). Loss of A/B cell polarity is a prominent feature of *lgl* LOF phenotype (see above) and indeed, extensive genetic analysis in *Drosophila* has led to the notion that Lgl functions in a 'baso-lateral' protein complex, together with the products of two other nTSG with very similar LOF phenotypes, Scribble (Scrib) and Discs large (Dlg). This complex works in establishing and maintaining cell polarity by antagonising the activity of two other protein complexes: the Crumbs/Stardust/PATJ (apical) and the Bazooka/Par6/aPKC (sub-apical) complexes.

The Crumbs/Stardust/PATJ complex

This complex establishes the apical identity of polarised cells and is required for adherens junctions (AJs) formation both in *Drosophila* and mammalian epithelial cells. It consists of three main components: a transmembrane protein, Crumbs (Crb), and two adaptor proteins, Stardust (Std) and PATJ. *Drosophila* Crb is characterised by a large extracellular portion with thirty epithelial growth factor (EGF)-like and four laminin A G-domain-like repeats, and a small conserved cytoplasmic region. In mammals three homologous genes have been identified (*CRB 1-3*); they show tissue specific expression patterns (CRB3 is the most widely expressed in epithelial tissues), and high levels of sequence identity with *Drosophila* Crumbs are observed in the cytoplasmic domain. *std* encodes a MAGUK (Membrane-Associated with GUanylate Kinase domain) protein with a PDZ (PSD-95/Dlg/ZO-1), a SH3 (Src Homology region 3) and a GUK (GUanylate Kinase-like) domain which binds Crb intracellular domain. Similarly, CRB3 complexes with the PDZ domain of Std mammalian homologue Pals1 (Protein associated with lin seven 1). The third component is encoded by *dpatj* gene in *Drosophila* and two mammalian homologues, PATJ (Pals-Associated Tight Junction Protein) and MUPP1 (MULTI-PDZ domain Protein 1), are also known to interact with Crb intracellular portion (Dow and Humbert, 2007; Tervonen *et al.*, 2011).

The Bazooka/Par6/aPKC complex

In *Drosophila*, below the Crumbs/Stardust/PATJ Complex, at the sub-apical region lies a complex composed of two scaffold proteins, Bazooka (Baz) and Par6, both containing PDZ domains as well as other protein-protein interaction motifs, and an atypical Protein Kinase C, aPKC. Genetic analysis has revealed that they are mutually dependent for proper localisation and *zonula adherens* (ZA) formation. In mammals one Baz homologue (Par3), three Par6 homologues (Par6 α , β and γ) and two aPKC homologues (aPKC λ / ι and aPKC ζ) have been found with differential expression patterns but mostly redundant functions. In mammalian cells this complex localises at tight junctions and is required for AJs formation as it is in *Drosophila* (Dow and Humbert, 2007; Tervonen *et al.*, 2011).

The Scribble/Discs large/Lethal giant larvae complex

In *Drosophila*, *scrib*, *dlg* and *lgl* nTSGs show very similar LOF phenotypes as well as a strong genetic interaction. Indeed, genetic analysis demonstrated that they act in a common pathway linking cell polarity and cell proliferation control in epithelial cells (Bilder and Perrimon, 2000). They all encode scaffolds rich in protein-protein interaction domains. Scribble belongs to the LAP (Leucine-rich repeats And PDZ domain) family and has four PDZ domains at the C-terminus and sixteen LRR (Leucine-Rich Repeats) at the N-terminus; it is encoded by a single gene both in *Drosophila* and vertebrates. Dlg is a MAGUK protein and contains three PDZ, an SH3 and a GUK domain. Several mammalian orthologues of *Drosophila* *dlg* have been identified so far. *lethal giant larvae* encodes a protein, Lgl, rich in WD40 repeats, predicted to fold into two β -propeller domains at the N-terminus. Lgl mammalian orthologues, Lgl-1 and Lgl-2, also contain WD40 repeats and have distinct expression patterns (Dow and Humbert, 2007; Tervonen *et al.*, 2011). Fly and human proteins show the significant global sequence similarity of 62.5% if conservative aminoacid changes are taken into account, and we found conclusive evidence of the

functional conservation between the two proteins in the full rescue of the *Drosophila* *lgl* mutant by the human *Lgl-1* cDNA (Grifoni *et al.*, 2004). Analogous rescuing ability has been demonstrated for rat Dlg (Thomas *et al.*, 1997) and human Scrib (Dow *et al.*, 2003). In *Drosophila* it has been demonstrated that the three proteins are mutually dependent for correct localisation (Bilder and Perimon, 2000), although direct physical interactions have never been proven. Dlg and Scrib localise at the membrane cortex, at *Drosophila* septate junctions (SJs). Lgl colocalises with Dlg and Scrib at SJs but it is also found in the cytoplasm. In neuronal synapses Scrib has been shown to bind Dlg via a protein named GUK Holder. In mammalian epithelial cells they are also localised at the basolateral domain of the plasma membrane and, similarly to the fly counterparts, the exact nature of their physical interaction has yet to be established; so far direct binding has only been proven for Scrib and Lgl-2 (Kallay *et al.*, 2006).

The mutually exclusive activity of these three complexes is required for the correct formation and positioning of cell junctions, which in turn provide cells with a correct apical-basal and cytoskeletal structure (Dow and Humbert, 2007). The mechanism through which the Baz/Par6/aPKC and the Scrib/Dlg/Lgl complexes regulate each other was initially investigated in *Drosophila* neuroblasts, the larval neuronal progenitors (Betschinger *et al.*, 2003). These cells do not have cell junctions but require a compartmentalisation of membrane domains in order to perform asymmetric cell division. These membrane complexes are required for proper positioning of cell fate determinants that will differentially segregate into the daughter cells giving origin to a new stem cell (self-renewal) and to a ganglion mother cell (GMC), the neuron/glia precursor. Failure to segregate cell fate determinants due to *lgl*/LOF results in excessive self-renewal and thus abnormal expansion of the neuroblast population (Wodarz, 2005). It was demonstrated that Lgl localisation at the plasma membrane depends on its phosphorylation in conserved residues by aPKC of the Baz complex (Betschinger *et al.*, 2003). Phosphorylated Lgl assumes an autoinhibited conformation in which protein interaction domains are masked and is thus excluded from the cortex. Lgl in turn counteracts aPKC activity by sequestering it in an inactive Lgl/aPKC/Par6 complex from which Bazooka is excluded (Betschinger *et al.*, 2005). Targeting of aPKC to the entire cell cortex reproduces *lgl* phenotype: asymmetric cell division is impaired leading to an excess of self-renewal and abnormal increase in neuroblast population (Lee *et al.*, 2006). Similarly, in epithelial tissues, cortical spreading of aPKC activity causes Lgl inhibition in the baso-lateral domain leading to tumourous growth, similarly to what is observed for *lgl* individuals (Grifoni *et al.*, 2007). Reduced aPKC levels suppress *lgl* phenotype in the imaginal discs (Rolls *et al.*, 2003) and a non-phosphorylatable form of Lgl completely fails to rescue the mutant phenotype in embryos lacking both maternal and zygotic *lgl* function (Hutterer *et al.*, 2004). The Crb complex is recruited by the Baz complex at the apical domain and seems to further antagonise the activity of the Lgl complex by blocking its spreading along the lateral membrane domain. Crb is phosphorylated by aPKC and this event is required for its correct apical localisation (Dow and Humbert, 2007). As expected from the high level of functional conservation, mammalian Lgl-1 and Lgl-2 are also excluded from the apical domain due to aPKC phosphorylation and are able to bind Par6 and aPKC preventing their association with Par3 and thus the baso-lateral spreading of apical complexes (Dow and Humbert, 2007). Moreover, we found

that Lgl-1 subcellular localisation seems to play a crucial role in human cancer, as its cytoplasmic enrichment correlates to aPKC lateral spreading and cancer progression in ovarian carcinomas (Grifoni *et al.*, 2007), mirroring what is observed in *Drosophila* *lgl* epithelial cancers. Another interesting parallel with fly *lgl* LOF phenotype can be found in a mouse *Lgl-1* knock-out (KO) model. Severe brain dysplasia, caused by the abnormal expansion of the progenitor cell population, is observed at birth. These cells are unable to exit cell cycle and differentiate, and form rosette-like structures, similar to the neuroblastic rosettes found in human pediatric tumours (Klezovitch *et al.*, 2004).

Lgl, cell proliferation and the Hippo pathway

Understanding how disruption of cell polarity and control of cell proliferation are linked would represent a significant advance in the comprehension of the molecular basis of epithelial cancer development. Originally, *lgl* mutant tissue overgrowth was hypothesised to be a direct consequence of loss of cell polarity caused by delocalisation of signalling molecules and simultaneous deregulation of several different pathways (Lee *et al.*, 2006). Nevertheless, several lines of evidence have demonstrated a specific signalling function of the Dlg/Lgl/Scrib module in proliferation control. First evidence came from the identification of *lgl*, *scrib* and *dlg* in a screen for dominant suppressors of a hypomorphic mutation of *cyclin E*, a key regulator of G1-S phase transition (Brumby *et al.*, 2004), implying a direct role in negative regulation of cell cycle. Indeed *lgl* clones in the eye disc (see below) show ectopic Cyclin E expression and thus ectopic S-phases without a complete disruption of apical-basal polarity (Grzeschik *et al.*, 2010), demonstrating that growth deregulation is not an immediate consequence of polarity loss.

The link between *lgl* and cell proliferation control was however finally established with the demonstration that the proliferative defects in the eye disc described above were due to the deregulation of the Hippo (Hpo) pathway (Grzeschik *et al.*, 2007), a very conserved signalling network that plays a central role in the control of epithelial tissue growth (Huang *et al.*, 2005; Dong *et al.*, 2007; Halder and Johnson, 2011). The Hpo pathway is composed of two core kinases, Hpo and Warts (Wts), the adaptors Salvador (Sav) and Mob As a Tumour Suppressor (Mats) and the transcriptional co-activator Yorkie (Yki), and it is modulated by numerous upstream factors among which the cytoskeletal proteins Expanded (Ex) and Merlin (Mer) and the atypical cadherins Fat (Ft) and Dachsous (Ds). When the pathway is active, Hpo can phosphorylate and activate Wts which in turn phosphorylates Yki sequestering it in the cytoplasm (Fig. 1A); on the other hand, upon its inactivation unphosphorylated Yki can translocate into the nucleus and, binding to different tissue-specific partners, activate the transcription of its target genes involved in cell growth, proliferation and resistance to apoptosis such as *cyc E*, *dIAP1* (*Drosophila* Inhibitor of Apoptosis 1) and the miRNA *bantam* (Halder and Johnson, 2011) (Fig. 1B). Yki is thus a growth promoter, whereas the upstream components act as tumour suppressors by antagonising the growth-promoting activity of Yki. Mutations in each of the known genes encoding components of the Hpo pathway are *per se* incapable to give rise to neoplastic phenotypes; rather they originate cells which proliferate into hyperplastic masses (Hariharan and Bilder, 2006); for a malignant growth to occur, a functional cooperation between loss of cell polarity and hyperplasia seems thus to be required.

Lgl was first shown to take part in the control of this pathway in the eye imaginal disc: in *lgl* mutant cells, an upregulation of Hpo pathway target genes such as *cyc E* and *diAP1*, as well as genes belonging to the negative feedback loops such as *ex*, was indeed observed; consistently, in *lgl* cells Yki was found also in the nucleus and the levels of the phosphorylated form were reduced (Grzeschik et al., 2007) (Fig. 1C). Removal of one copy of *yki* partially reduced Hpo target genes upregulation as well as the ectopic S-phases phenotype previously described (Grzeschik et al., 2007), indicating that Yki activity is required for *lgl* proliferative defects. Yki activation in *lgl* cells seems to be due to Hpo mislocalisation and to the putative formation of an inactive complex with RASSF (Ras associated factor), another regulator of the pathway, also mislocalised in mutant cells (Grzeschik et al., 2010) (Fig.

1C). The same effect is observed when an active form of aPKC is expressed; since Lgl and aPKC are mutually exclusive (see “Lgl and cell polarity” paragraph), when aPKC localises at the whole cell cortex, Lgl is completely released from the membrane, thus phenocopying *lgl* mutation. Crumbs, a protein of the apical polarity complex, has also been placed upstream of the Hippo signalling. Upon its overexpression, the authors observe the delocalisation of Expanded from the apical to the lateral cell domain; since Expanded binds Yorkie and fastens it to the cell cortex (Badouel et al., 2009), it is plausible that its removal from the apical region is responsible for Yorkie activation (Grzeschik et al., 2010; Ling et al., 2010). A similar effect has been observed in the wing disc: upon Crumbs overexpression, the protein Expanded resulted either delocalised or reduced in level (Chen et al., 2010; Ling et al., 2010; Robinson




Fig. 1. Hippo pathway deregulation upon *lgl* loss of function in the imaginal epithelia. (A,B) Schemes depicting the Hippo pathway in an active state (A) and upon any event causing its deregulation (B). The main members cited in the text are represented. (C) An eye-antennal disc in which *lgl* mutant clones (green) have been generated. *lgl* mutation in this context provokes RASSF/Hpo mislocalisation at the baso-lateral membrane (pink arrowhead) and Yki nuclear enrichment. (D) A wing disc in which *lgl* knockdown has been induced in the posterior compartment (green). In this context, *Ft* mislocalises at the whole cell cortex (yellow arrowheads) and deregulation of the Hippo pathway is JNK-dependent. Abbreviations: CRB, Crumbs; RASSF, Ras-associated factor; EX, Expanded; MER, Merlin; WTS, Warts; HPO, Hippo; SAV, Salvador; MATS, Mob as a tumour suppressor; D, Dachshaus; FT, Fat; DS, Dachshaus; YKI, Yorkie; aPKC, atypical Protein kinase C; LGL, Lethal giant larvae; SCRIB, Scribble; DLG, Discs large; TSBP, Tissue-specific binding partner. In pink, proteins which overexpression causes pathway deregulation; in yellow, proteins which loss causes pathway deregulation. Details are found in the main text.

et al., 2010).

lgl-dependent regulation of Yki has also been observed in the wing imaginal disc but it was proposed to occur through a different mechanism. *lgl* depletion-dependent tumours were generated by specifically knocking down *lgl* transcript in the posterior compartment of the wing disc leading to overgrowth and loss of cell polarity (Sun and Irvine, 2011). In these posterior cells Ft resulted mislocalised at the entire cell cortex, Yki was mainly found in the nucleus and Hpo pathway reporter genes such as *ex* were upregulated (Fig. 1D). Indeed knockdown of Yki or overexpression of Wts in this context blocked the overgrowth and resulted in discs with reduced posterior compartment and high levels of cell death, suggesting that Yki activity is required for growth and survival of *lgl*-depleted cells. Interestingly Yki activation was found to be due to JNK (c-Jun N-terminal kinase) signalling (Sun and Irvine, 2011) (Fig. 1D), an evolutionarily conserved stress-induced MAPK cascade that has roles in multiple cellular processes including proliferation, differentiation, morphogenesis, and most of all, apoptosis, and has been implicated in several aspects of tumour development in *Drosophila* and humans (Ryoo *et al.*, 2004; Igaki *et al.*, 2006; Wagner and Nebreda, 2009; Chen, 2012).

Two explanations have been proposed to account for the differences in Yki regulation upon *lgl* depletion in the eye vs wing imaginal discs: first, in the experimental conditions employed in the wing disc cell polarity was lost, whereas this was not the case in the eye disc; second, wing and eye discs seem to have a different sensitivity to JNK signalling since its direct activation is able to regulate Yki in the wing disc only (Sun and Irvine, 2011). *lgl* may thus regulate cell proliferation by influencing the Hpo pathway in a tissue-specific manner through JNK-dependent and independent pathways. *scrib* loss of function however induces JNK-independent impairment of the Hpo pathway in both the eye and wing imaginal discs (Dogget *et al.*, 2011). It thus seems that the crosstalk between cell polarity proteins, JNK signalling and the Hpo pathway are complex and possibly context-dependent and further work is needed to clarify this. In a recent paper, genetic evidence has been provided suggesting that *Scrib* acts downstream of Ft and that it is required by this latter for the interaction with Ex and Dachs (D), an unconventional myosin that participates in the regulation of the Hpo pathway downstream of Ft (Verghese *et al.*, 2012).

Similarly to what has been demonstrated for *lgl* and *scrib* LOF phenotypes, deregulation of the Hpo pathway also seems to contribute, at least in part, to the overgrowth that characterises the oncogenic cooperation between activated Ras/Raf and polarity gene loss (Dogget *et al.*, 2011, Menéndez *et al.*, 2010, Chen *et al.*, 2011). In 2003, two pivotal studies were published showing that constitutive activation of Ras signalling rescues *scrib*, *lgl* and *dlg* mutant cells viability and induces in mutant cells massive overgrowth and acquisition of striking invasive capabilities (Brumby and Richardson, 2003; Pagliarini and Xu, 2003). More recently, Dogget and colleagues found that Yki target genes were upregulated in *scrib*; *Raf^{Act}* (or *Ras^{V12}*) tumours in the eye imaginal disc and inhibition of Yki activity significantly reduced tumour growth. However, despite reduction of the tumorous mass, mutant clones were still able to invade and differentiation remained blocked, indicating that Hpo pathway impairment does not contribute to these phenotypes. Moreover, the fact that the growth of these clones was not totally abrogated by blocking Yki function suggests that other pathways may be involved in driving *scrib*; *Raf^{Act}* cells clonal expansion in

this context (Dogget *et al.*, 2011). In another study, analysis of large overgrown and fast-proliferating *lgl*; *Ras^{V12}* clones in the wing disc revealed an evident Yki nuclear staining and, accordingly, a strong upregulation of its target genes. The authors did not test whether Yki was required for the overgrowth of *lgl*; *Ras^{V12}* clones but showed that its expression within *lgl* clones is sufficient to promote it (Menéndez *et al.*, 2010). Similarly, *scrib*; *Ras^{V12}* clones in the wing disc also showed upregulation of Yki target genes and Yki overexpression was able to promote overgrowth of *scrib* mutant cells (Chen *et al.*, 2011).

Regulation of the Hpo pathway by the Scrib/Dlg/Lgl module in vertebrates

Deregulation of several members of the Hpo pathway has been found associated with proliferative disorders in humans (Harvey *et al.*, 2013), but clear evidence of a functional interaction between the Scrib/Dlg/Lgl module and the Hpo pathway in vertebrates is only beginning to appear in literature, and the majority of studies so far reported focus on *scrib* because a single orthologue of this gene is present in vertebrate genomes. As an example, Fat-1 and Scrib have been shown to act in a common signalling cascade during zebrafish pronephros development, possibly through a direct interaction, as human Scrib was shown to bind both mouse Fat-1 (via its PDZ-binding site) and *Drosophila* Fat in immunoprecipitation assays (Skouloudaki *et al.*, 2009). In a more recent study, Cordenonsi and colleagues showed that the transcriptional coactivator TAZ (a Yki human orthologue) is required for self-renewal and tumour initiation of human breast epithelial cancer cells and that its increased activity is associated with a more malignant phenotype. Interestingly, they found that Scrib forms a complex with TAZ that is required for its inhibitory association with the Hpo core kinases LATS (Wts human orthologue) and MST. As a consequence, Scrib loss/mislocalisation triggers TAZ oncogenic activity (Cordenonsi *et al.*, 2011).

lgl, cell competition and Myc

In the past decade a key concept has strikingly emerged in the field of cancer biology: cancer can not be considered as a cell-autonomous disease; progression towards malignancy is instead unavoidably influenced by the crosstalk between cancer cells and their microenvironment (Pietras and Östman, 2010; McAllister and Weinberg, 2010). A paradigm of this concept can be found in the analysis of *lgl* clonal phenotype: when patches of mutant tissue grow in a wild-type background, they behave remarkably differently compared to the whole mutant animal, where neoplastic growth and loss of cell polarity are invariably observed. In the eye imaginal disc, *lgl* clones show ectopic proliferation but maintain apical-basal cell polarity. Overall clonal size is however not affected since increased cell death is also observed (Grzeschik *et al.*, 2007). The differences between *lgl* clones and whole mutant tissues are even more striking in the imaginal wing disc: mutant cells are rapidly eliminated by apoptotic death and do not contribute to the adult organ almost at all. We demonstrated that *lgl* mutant cells elimination in this organ is attributable to the phenomenon of cell competition (Froldi *et al.*, 2010).

Cell competition is a mechanism of short-range cell-cell interaction firstly described in *Drosophila* imaginal wing discs about 40 years ago (Morata and Ripoll, 1975), which consists in the removal

during development of viable but slow-dividing, unfit or damaged cells (losers) by the surrounding faster growing populations (winners), ensuring that the adult organ reaches proper size. It occurs in distinct, inter-dependent phases (Lolo *et al.*, 2012): first, a loser cell is produced by a mutational event that modifies its proliferation or metabolic rate, next the winner cells kill the losers, dying cells are then basally extruded from the epithelium, apoptotic debris is removed by competent cells and winner cells over-proliferate to compensate for cell loss (Fig. 2 A-C). It was initially proposed that winner cells were also responsible for the engulfment of loser cell residues (Li and Baker, 2007), but it was recently demonstrated that clearance is rather carried out by recruited hemocytes (Lolo *et al.*, 2012). Cell competition was initially observed analysing a group of dominant mutations called *Minute (M)* that concern various ribosomal protein genes. These mutations are recessive lethal and display a dominant growth defect: $M^{+/-}$ cells are viable but have a slow growing rate and consequently $M^{+/-}$ flies are of normal size but their development is delayed with respect

to wild-type counterparts. However, if mitotic clones of $M^{+/-}$ cells are generated in a wild-type wing imaginal disc tissue, they are eliminated by apoptosis. Extra proliferation in the wild-type tissue occurs to replace outcompeted cells, the total number of which in the developing tissue remains unchanged and no morphological alterations are observed in the resulting organ (Gallant, 2005). Interestingly, Tyler and colleagues (Tyler *et al.*, 2007) found that mutations in several genes belonging to the Hpo pathway were able to protect $M^{+/-}$ cells from being outcompeted in a wild-type background and even to provide them with competitive capabilities, as indicated by active Caspase 3 staining visible outside the mutant clones (Tyler *et al.*, 2007), demonstrating the involvement of this pathway in the phenomenon of cell competition.

Igl mutant cells, despite being unable to exit cell cycle, proliferate at a slower rate compared to the wild-type counterparts (Bilder, 2004; Froidi *et al.*, 2010) and, when surrounded by wild-type tissue, are found to undergo apoptotic cell death mediated by the activation of JNK signalling (Froidi *et al.*, 2010; Tamori *et al.*, 2010). *Igl* mutant




Fig. 2. Cell competition and *Igl* mutant cell phenotypes. (A-C) The main phases of cell competition. An imaginal epithelium is represented, with the ventral (V) surface up and the dorsal (D) down. PM: peripodial membrane, a squamous epithelium that coats the ventral surface of all imaginal discs; DP: disc proper, formed by the columnar epithelium; BM: basement membrane; A: apical side of the DP; B: basal side of the DP. **(A)** A cell with a mutation in genes involved in cell proliferation, cell growth or cell metabolism appears in the epithelium (loser, green). **(B)** The loser cell is killed by the adjacent wild-type cells (brown) and basally extruded from the epithelium in the form of apoptotic bodies. **(C)** Cellular debris is removed and extra-proliferation occurs in the winner cells which replace the loser. **(D,E)** *Myc* transcript and protein in *Igl* mutant clones. **(D)** *Igl*⁻ clones in a wild-type background lose the competition and are eliminated from the epithelium. *Myc* transcriptional activity is normal but *Myc* protein does not accumulate within mutant clones. **(E)** *Igl*⁻; *Myc* clones win the competition and overgrow with respect to the wild-type neighbours. *Myc* transcript and protein are both upregulated. **(F-H)** Relationship between *Myc* pattern and *Igl*⁻ clonal behaviour. **(F)** *Myc* pattern in the wing disc: *Myc* protein is enriched in the distal region (wing pouch) and very low in the proximal territories (hinge and pleura), where *Igl*⁻ clones overexpressing *Myc* are able to overgrow and form tumourous masses **(G)**. Despite *Myc* overexpression, *Igl* mutant clones are not able to grow in the wing pouch region **(H)**. See main text for more details.

cell elimination was found to be more efficient in the distal region of the wing disc, known as wing pouch, where cell competition is known to be the strongest. Moreover, as expected when competitive interactions take place, wild-type twins of *lgl* clones were found to overgrow to compensate for mutant cell loss (Froldi *et al.*, 2010). When generated in a non-competitive *Minute* background (see above), *lgl* cells were able to overgrow and form tumourous masses characterised by invasive behaviour and cell polarity loss, like the whole mutant tissue, further demonstrating the involvement of cell competition in *lgl* mutant cell clonal behaviour (Froldi *et al.*, 2010).

In addition to ribosome impairment, mutations in genes responsible for cell growth have also been found associated with cell competition, such as the Decapentaplegic (Dpp)/Transforming Growth Factor β (TGF β) pathway, for which cells compete to escape apoptotic death (Moreno *et al.*, 2002). In recent years, the proto-oncogene *myc* has been strongly implicated in this phenomenon in *Drosophila* (de la Cova *et al.*, 2004; Moreno and Basler, 2004). Clones bearing hypomorphic *myc* mutations, viable in a homotypic environment, were found to be eliminated by non-autonomous cell death when generated in a wild-type imaginal disc (Johnston *et al.*, 1999). In 2004 two papers were published in which it was clearly demonstrated that cell competition is not simply caused by cellular defects associated with *myc* loss because, as it was shown, also wild-type cells are out-competed if surrounded by Myc-overexpressing cells, and that it is instead triggered by a sharp difference in Myc protein levels between adjacent populations (de la Cova *et al.*, 2004; Moreno and Basler, 2004). de la Cova and colleagues showed that clones overexpressing Myc were significantly larger than control clones, due to promotion of cellular growth; however, sibling clones generated in recombination events were smaller than control siblings. They also showed that wild-type cells appeared to be subject to competition only if they lied within about eight cell diameters away from Myc-expressing cells and in the same developmental compartment (de la Cova *et al.*, 2004); it was indeed later suggested that cell competition is mediated by soluble factors (Senoo-Matsuda and Johnston, 2007). Using a *myc* tandem duplication, similar results were obtained by Moreno and Basler (Moreno and Basler, 2004). Sibling clones were generated that were composed of cells with four (*4xmyc*) or two copies (*2xmyc*) of the endogenous *myc* gene. Interestingly, not only *4xmyc* clones were significantly larger than their *2xmyc* wild-type siblings, but they were also larger than control clones that were induced simultaneously in different individuals in which all cells carried four copies of *myc*. Likewise, clones carrying two copies of *myc* were not only smaller than their *4xmyc* siblings, but also smaller than control clones growing in a background where all cells had two copies of *myc*, demonstrating that clonal growth strongly depends on cellular environment.

We found that *lgl* clones express much lower levels of Myc compared to the background, and this difference in Myc expression triggers *lgl* mutant cell elimination. Myc down-regulation in *lgl* clones occurs at the post-transcriptional level, as a *myc* promoter reporter results active in mutant cells (Froldi *et al.*, 2010) (Fig. 2D). The differences in *lgl* cell removal efficiency in the distal vs proximal regions of the wing disc correlate with Myc pattern: the protein is highly expressed in the wing pouch (distal) and very low in the hinge/pleura (proximal) (Fig. 2F) where, as a consequence, Myc gradient between mutant and wild-type cells is reduced and cell competition is less fierce. Experimental overexpression of Myc in *lgl* mutant

clones not only rescued their viability but promoted their malignant growth (loss of cell polarity and invasiveness) in proximal regions (Fig. 2 E,G), whereas in the wing pouch Myc protein accumulation was found to be prevented by a still-uncharacterised mechanism and *lgl*; Myc clones were thus eliminated anyway (Froldi *et al.*, 2010) (Fig. 2H). Of note, isolated *lgl*; *Ras*^{V12} clones were also found to undergo cell death in the wing pouch region (Menéndez *et al.*, 2010) despite their well-known proliferative advantage. We suggest, based on our unpublished data, that the *lgl*-dependent Myc degradation we observed in the most central region of the wing pouch can counteract its accumulation induced by Ras activation (Prober and Edgar, 2002), impinging on the intrinsic transforming abilities of *lgl*; *Ras*^{V12} cells. Further evidence of Myc involvement in *lgl* cells clonal behaviour came from the observation that overgrown and invasive *lgl* clones generated in a *Minute* background invariably showed Myc upregulation and *myc* knock-down in these cells completely suppressed the tumourous phenotype (Froldi *et al.*, 2010). Notably, Myc effect on *lgl* clonal behaviour seems very specific, as activation of a growth-promoting pathway that however failed to increase Myc levels within mutant cells, such as PI3K, was unable to promote their neoplastic growth (Froldi *et al.*, 2010).

A different clonal behaviour with respect to the whole mutant phenotype is also a well-known feature of *scrib* LOF: in the eye disc, clones lose polarity and overproliferate but very little mutant tissue is recovered in the adult eye as it is removed during development by JNK-mediated apoptosis. Interestingly, also in this case, cell death is induced in a non-autonomous manner by the surrounding wild-type tissue since upon its removal *scrib* clones viability is rescued (Brumby and Richardson, 2003). The mechanism described by Igaki and colleagues for JNK non-autonomous activation in *scrib* or *dlg* mutant clones was named Intrinsic Tumour Suppression (ITS), which consists in the endocytic activation of Eiger (Egr), the *Drosophila* TNF (Tumour Necrosis Factor), a known activator of the JNK pathway (Igaki *et al.*, 2009). *scrib* or *dlg* clones generated in an *egr* null background no longer die but overgrow and develop into tumours; the same effect was observed in the wing imaginal disc. Mutant cells were found to have increased endocytic activity and Egr was mislocalised and enriched at the endocytic vesicles. Egr localisation correlated with intense phosphorylated - and thus activated - JNK staining. Indeed inhibition of endocytosis by means of a dominant negative form of Rab5 (an early endosomal marker) abolished JNK activation and mutant clones elimination, allowing tumourous growth. Ablation of surrounding wild-type tissue prevented endocytosis upregulation and Egr/JNK-dependent death of *scrib* cells (Igaki *et al.*, 2009). Nevertheless, an involvement of cell competition in the elimination of *scrib* mutant cells has also been suggested based on the observation that a reduction of fitness in the surrounding wild-type cells (that is to say a *Minute* background) prevented *scrib* cells elimination and promoted the formation of large proliferating clones (Chen *et al.*, 2011).

Cell competition and ITS seem thus to be functionally related mechanisms triggered in opposing cells by different molecules but operating through the common JNK pathway (Vidal, 2010). Regarding *lgl* cells elimination, ITS seems not to be involved in the wing pouch region, where inhibition of endocytosis neither prevented mutant cells elimination nor JNK activation. Similarly, knock-down of *egr* had no effect on *lgl* mutant clone growth and did not prevent JNK signaling activation, suggesting that this latter functions independently of *egr* in this context (Froldi *et al.*, 2010).

On the other hand, inhibition of ITS in the proximal regions resulted in moderate overgrowth indicating that ITS and cell competition are likely to be involved in the elimination of *Igf1* mutant cells in complementary regions. Of note, also upon ITS inhibition, *Igf1* proliferation is accompanied by an increase in Myc protein levels (Froldi *et al.*, 2010).

The competitive traits shown by the Hpo pathway mutant cells (see above) have also been recently explained by the identification of *myc* as a target of this pathway (Ziosi *et al.*, 2010; Neto-Silva *et al.*, 2010). Indeed we were able to demonstrate that Myc upregulation is responsible for Hpo mutant or Yki-overexpressing clones competitive behaviour, as their overgrowth was drastically reduced if they were generated in a Myc-overexpressing background (Ziosi *et al.*, 2010).

Cell competition in mammals

Myc expression is deregulated in a wide range of human cancers and is often associated with aggressive, poorly differentiated tumours (Albihn *et al.*, 2010). It is thus becoming increasingly evident that Myc-induced cell competition could play a role in cancer development (Moreno, 2008; Baker and Li, 2008; Levayer and Moreno, 2013). Clones of cells expressing high Myc levels could expand at the expenses of the surrounding normal cells, without generating morphological changes. Further, expansion may increase the probability of accumulation of other mutations in subsets of cells that would confer new oncogenic properties to their descendants, as predicted by the *field cancerisation* theory (Rhinier and Moreno, 2009). On the other hand, cell competition may represent a mechanism of defence that tumour cells need to overcome in the very early steps of cancer onset in order to survive within the tissue (Moreno, 2008). Evidence exists that a phenomenon akin to cell competition is conserved also in mammals. It has been shown in mice that a deletion within the *Rpl24* riboprotein gene significantly impairs ribosome biogenesis and results in decreased rates of protein synthesis and proliferation, clearly mirroring *Drosophila Minute* phenotype. Heterozygous mutant cells, while viable in a homotypic environment, giving rise to almost normal mice, are indeed out-competed by wild-type cells in chimeric blastocysts (Oliver *et al.*, 2005). Another example is given by rat liver progenitors transplants: under certain conditions transplanted cells can overproliferate and induce cell death of the host cells to an extent that the entire liver is repopulated by donor-derived cells (Oertel *et al.*, 2006). Compelling evidence of cell competition occurring in mammalian cell cultures has been produced in two recent papers (Tamori *et al.*, 2010; Norman *et al.*, 2012): inducible cell culture systems have been employed to demonstrate that such non-cell autonomous phenomenon is conserved. Tamori and colleagues knocked down the Lgl interactor Mahjong (that they proved to be involved in *Igf1*-mediated cell competition in *Drosophila*) in Madin-Darby canine kidney epithelial cells and showed that Mahjong-deficient cells undergo apoptotic cell death only when surrounded by wild-type cells (Tamori *et al.*, 2010). Similar results were obtained by Norman and colleagues upon *Scrib* knockdown in the same cell line: the authors demonstrated that while *Scrib* knockdown cells were viable when surrounded by cells of the same kind, they died and were apically extruded in the presence of wild-type cells (Norman *et al.*, 2012). Clear evidence of Myc-induced cell competition in mammals akin to that described in *Drosophila* epithelia has been finally obtained in the

mouse embryo. Inducing functional genetic mosaics in the mouse, Clavería and colleagues were indeed able to demonstrate that an imbalance in Myc levels in the epiblast triggers the expansion of Myc overexpressing cells at the expenses of the cells with lower Myc levels, which are eliminated by apoptosis without impairing morphogenesis (Clavería *et al.*, 2013). In addition, the authors found that wild-type cells forming the early embryo are heterogeneous in Myc content during normal development and endogenous cell competition refines the final epiblast selecting cells with higher Myc levels (Clavería *et al.*, 2013). In a parallel study, Sancho and colleagues showed that defective embryonic stem cells undergo apoptosis during embryo development and that this mechanism depends on the establishment of differential c-Myc levels throughout the embryo (Sancho *et al.*, 2013). Cell competition thus appears to be a conserved biological phenomenon through which developing tissues shape their final pool of cells. Strict evidence is however still missing about a role for Myc-induced cell competition in mammalian cancer. In mice intestinal crypts, loss of APC (Adenomatous Polyposis Coli) leads to unrestricted proliferation and even when only 10% of crypts are APC-deficient, several lesions and adenomas are recovered in the intestine. However, if these crypts are simultaneously mutant for APC and c-Myc, they are rapidly replaced by surrounding wild-type stem cells that repopulate the crypts, leading to complete rescue of pathological changes (Sansom *et al.*, 2007). This, far from being a strict demonstration of Myc-mediated cell competition in mammalian tumorigenesis, represents a hint of the existence of mechanisms, dependent on the coexistence of cell populations with different Myc levels, able to restrain growth of cancerous cells.

Conclusions

It is quite clear that cancer cells are socially inadequate, because they subvert tissue and organ dynamics, like troubled teenagers in a respectable family. Primitive behaviours characterise their growth, such as an anxious search for food and an essential ability to break any barrier and, just as it happens in a respectable family, relatives are in most cases tolerant and, as a consequence, they are unavoidably overcome. In the most common oncogenic view of Myc-induced cell competition, cancer cells are able to grow at the expenses of their neighbours (Froldi *et al.*, 2010; Menéndez *et al.*, 2010; Neto-Silva *et al.*, 2010; Ziosi *et al.*, 2010). On the other hand, potentially harmful cells deficient in polarity genes can be eliminated early in development by the adjacent populations through apoptotic death induced by cell competition (Froldi *et al.*, 2010) or intrinsic tumour suppression (Igaki *et al.*, 2009) and do not participate in the formation of the final organ almost at all.

In regard to *Igf1* mutant cells, Myc is the on-off switch that determines if they should live or die: grossly, *Igf1* cells expressing high levels of Myc *live long and prosper* and form tumours; *Igf1* cells expressing low levels of Myc die (Froldi *et al.*, 2010). However, absolute Myc levels are not actually informative; unless these latter are compared with those of the nearby cells, the fate of *Igf1* cells cannot be easily foreseen. So, the ancient sermon: *No man is an island*, mentioned in many well-known writings and movies, can be reworded to: *No cell is an island*. This is an acknowledged concept in tissue development and organ morphogenesis, but cancer has been instead long considered and cured as an autonomous disease, irrespective of the tissue it grew within. In the

last decade, not only the microenvironment has begun to be taken into account in cancer biology, but also systemic responses have proved to participate in cancer growth and outcome. In *Drosophila*, many studies have investigated these aspects of tumorigenesis in different organs and contexts, which have been conveniently recapitulated in a recent review by Tipping and Perrimon (Tipping and Perrimon, 2013).

It has been recently shown that *lgl* cells forming tumours in the wing and in the eye imaginal discs cease to express the typical determinants of those tissues and switch to a primitive state; the experimental expression of these determinants is indeed capable of suppressing the tumorous phenotype and induce cell death (Khan *et al.*, 2013), confirming that cancer cells need to subvert the genetic constraints of the tissue in order to break the morphological barriers imposed by the organ. This is quite interesting because, as mentioned above, *lgl* cells express very high levels of Myc in any context they succeed to form tumours, and Myc is one of the four genes that were found necessary for a human somatic cell to be reprogrammed into a pluripotent progenitor (Takahashi *et al.*, 2007). Further studies in *Drosophila* could help elucidate the role of Myc in this important phenomenon.

Given the inactivation of the Hippo pathway observed in *lgl* clones, with the resulting nuclear translocation of the downstream effector Yorkie (Ménendez *et al.*, 2010; Sun and Irvine, 2011; Khan *et al.*, 2013), the high levels of Myc in the tumorous *lgl* clones are obviously due, at least in part, to its transcriptional activation; two studies indeed confirmed that Myc is a direct transcriptional target of Yorkie (Neto-Silva *et al.*, 2010; Ziosi *et al.*, 2010). Other pathways are possibly involved in increasing *myc* transcription and Myc protein accumulation in *lgl* mutant cells; as an example, in a recent paper the group of Kenneth Irvine identified the Ajuba (Jub) protein kinase, which is activated by the terminal MAPK downstream of the EGFR pathway, as an activator of Yorkie through its inhibitory binding to Warts and Salvador (Reddy and Irvine, 2013). Furthermore, it is well known that Myc protein stability is increased upon activation of the EGFR pathway (Prober and Edgar, 2002). Whether similar mechanisms are at work in *lgl* cells is currently under investigation in our lab.

The biochemical mechanisms for Yorkie activation in *lgl*-depleted cells has not been provided yet; genetic evidence however exists that in *lgl* cells originated in the eye and wing discs, several upstream components of the Hippo pathway and proteins owing to different polarity complexes are mislocalised (Chen *et al.*, 2010; Grzeschik *et al.*, 2010; Ling *et al.*, 2010; Robinson *et al.*, 2010). But what is the temporal relationship between loss of cell polarity and hyperproliferation? Which one triggers the other? Or is it a chess game instead? It is thinkable that a tumour must reach a certain dimension in cell number before beginning to dictate new rules within the tissue; hyperproliferation is thus supposed to be the best opening move. Two studies performed in *Drosophila* have demonstrated that, during tumour progression, deregulation of the Hippo pathway signals back to the apical cortex inducing an increase in Crumbs and aPKC levels, thus promoting apical hypertrophy (Genevet *et al.*, 2009; Hamaratoglu *et al.*, 2009). A mild disruption of apical-basal cell polarity could thus trigger a partial deregulation of the Hippo pathway which, in turn, would increase the abundance of apical determinants so provoking an imbalance between apical and basal complexes that could translate into a structural collapse of the cell apical-basal axis. At this stage, Hippo pathway

deregulation would become stronger and, in certain contexts, it could induce further tumorous phenotypes such as invasion and growth at secondary sites. Several studies in flies and mammals have indeed shown that the Hippo pathway is regulated by mechanical signals coming from cell membrane, cell junctions and cytoskeleton, conveyed to provide cells with positional information and spatial/social cues (reviewed by Schroeder and Halder, 2012). Moreover, since aPKC and Crumbs anisotropy has been involved in the formation of cellular and supracellular actomyosin cables (Röper, 2012) which function is, among others, to structure and maintain epithelial functional clusters and compartment boundaries during development, it is also possible that changes in abundance and localisation of these apical determinants during tumour growth disrupt actomyosin cables arrangement thus helping disorganise tissue architecture.

The function of Myc in all these processes remains largely unexplored. It is a matter of fact that Myc protein accumulation characterises the vast majority of *Drosophila* and human cancers, and that in experimental systems it is found responsible for the most part of the phenotypes induced by deregulation of the Hippo pathway in different organs and cell types (Ziosi *et al.*, 2010; Reddy and Irvine, 2011; Ren *et al.*, 2013); nevertheless, *myc* overexpression, also in combination with *dIAP1*, is not able to rescue viability of *yki* mutant cells (Ziosi *et al.*, 2010), suggesting that multiple levels of complexity must be taken into account when one is trying to dissect gene function in a cancer context. For this reason, the use of animal models in which several techniques combining cellular and developmental genetics are available can have a deep impact on cancer research.

Acknowledgements

Work in our laboratory is supported by the "Associazione Italiana di Ricerca sul Cancro (AIRC, IG 12093) and by the "Fondazione CaRisBO" (2011/0697). DG is supported by a Research Fellowship from Dipartimento di Farmacia e Biotecnologie, University of Bologna. We thank anonymous reviewers for useful comments, Patrizia Romani for critical reading of the manuscript and Fabrizio Pastori for help with graphics.

References

- ALBIHN A, JOHNSEN J I and HENRIKSSON M A (2010). MYC in oncogenesis and as a target for cancer therapies. *Adv Cancer Res* 107: 163-224.
- BADOUÉL C, GARDANO L, AMIN N, GARG A, ROSENFELD R, LE BIHAN T and MCNEILL H (2009). The FERM-domain protein Expanded regulates Hippo pathway activity via direct interactions with the transcriptional activator Yorkie. *Dev Cell* 16: 411-420.
- BAKER N E and LI W (2008). Cell competition and its possible relation to cancer. *Cancer Res* 68: 5505-5507.
- BEAUCHER M, GOODLIFFE J, HERSPERGER E, TRUNOVA S, FRYDMAN H and SHEARN A (2007a). *Drosophila* brain tumor metastases express both neuronal and glial cell type marker. *Dev Biol* 301: 287-297.
- BEAUCHER M, HERSPERGER E, PAGE-MCCAW A and SHEARN A (2007b). Metastatic ability of *Drosophila* tumors depends on MMP activity. *Dev Biol* 303: 625-634.
- BETSCHINGER J, MECHTLER K and KNOBLICH J A (2003). The Par complex directs asymmetric cell division by phosphorylating the cytoskeletal protein Lgl. *Nature* 422: 326-330.
- BETSCHINGER J, EISENHABER F and KNOBLICH J A (2005). Phosphorylation-induced autoinhibition regulates the cytoskeletal protein Lethal (2) giant larvae. *Curr Biol* 15: 276-282.
- BILDER D, LI M and PERRIMON N (2000). Cooperative regulation of cell polarity and growth by *Drosophila* tumor suppressors. *Science* 289: 113-116.

- BILDER D (2004). Epithelial polarity and proliferation control: links from the *Drosophila* neoplastic tumor suppressors. *Genes Dev* 18: 1909-1925.
- BRUMBY A M and RICHARDSON H E (2003). *scribble* mutants cooperate with oncogenic Ras or Notch to cause neoplastic overgrowth in *Drosophila*. *EMBO J* 22: 5769-5779.
- BRUMBY A, SECOMBE J, HORSFIELD J, COOMBE M, AMIN N, COATES D, SAINT R and RICHARDSON H (2004). A genetic screen for dominant modifiers of a cyclin E hypomorphic mutation identifies novel regulators of S-phase entry in *Drosophila*. *Genetics* 168: 227-251.
- CHEN C L, GAJEWSKI K M, HAMARATOGLU F, BOSSUYT W, SANSORES-GARCIA L, TAO C and HALDER G (2010). The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in *Drosophila*. *Proc Natl Acad Sci USA* 107: 15810-15815.
- CHEN C, SCHROEDER M C, KANGO-SINGH M, TAO C and HALDER G (2011). Tumor suppression by cell competition through regulation of the Hippo pathway. *Proc Natl Acad Sci USA* 109: 484-489.
- CHEN F (2012). JNK-induced apoptosis, compensatory growth, and cancer stem cells. *Cancer Res* 72: 379-386.
- CHO E, FENG Y, RAUSKOLB C, MAITRA S, FEHON R and IRVINE K D (2006). Delineation of a Fat tumor suppressor pathway. *Nat Genet* 38: 1142-1150.
- CLAVERÍA C, GIOVINAZZO G, SIERRA R and TORRES M (2013). Myc-driven endogenous cell competition in the early mammalian embryo. *Nature* 500: 39-44. doi: 10.1038/nature12389.
- CORDENONSI M, ZANCONATO F, AZZOLIN L, FORCATO M, ROSATO A, FRASCON C, INUI M, MONTAGNER M, PARENTI A R, POLETTI A et al., (2011). The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. *Cell* 147: 759-772.
- DOGGET K, GRUSCHE F A, RICHARDSON H E and BRUMBY A M (2011). Loss of the *Drosophila* cell polarity regulator Scribbled promotes epithelial tissue overgrowth and cooperation with oncogenic Ras-Raf through impaired Hippo pathway signaling. *BMC Dev Biol* 11: 57.
- DONG J, FELDMANN G, HUANG J, WU S, ZHANG N, COMERFORD S A, GAYYED M F, ANDERS RA, MAITRA A, PAN D (2007). Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* 130:1120-1133.
- DOW L E, BRUMBY A M, MURATORE R, COOMBE M L, SEDELIES K A, TRAPANI J A, RUSSELL S M, RICHARDSON H E and HUMBERT P O (2003). hScrib is a functional homologue of the *Drosophila* tumour suppressor Scribble. *Oncogene* 22: 9225-9230.
- DOW L E and HUMBERT P O (2007). Polarity regulators and the control of epithelial architecture, cell migration and tumorigenesis. *Int Rev Cytol* 262: 253-302.
- DE LA COVA C, ABRIL M, BELLOSTA P, GALLANT P and JOHNSTON L A (2004). *Drosophila* Myc regulates organ size by inducing cell competition. *Cell* 117: 107-116.
- FROLDI F, ZIOSI M, TOMBA G, PARISI F, GAROIA F, PESSION A and GRIFONI (2008). *Drosophila lethal giant larvae* neoplastic mutant as a genetic tool for cancer modeling. *Curr Genomics* 9: 147-154.
- GALLANT P (2005). Myc, cell competition, and compensatory proliferation. *Cancer Res* 65: 6485-6487.
- GATEFF E (1978). The genetics and epigenetics of neoplasms in *Drosophila*. *Biol Rev Camb Philos* 53: 123-168.
- GENEVET A, POLESELLO C, BLIGHT K, ROBERTSON F, COLLINSON L M, PI-CHAUD F and TAPON N (2009). The Hippo pathway regulates apical-domain size independently of its growth-control function. *J Cell Sci* 122: 2360-2370.
- GONT A, HANSON J E L, LAVICTOIRE S J, PAROLIN D A E, DANESHMAND M, RESTALL I J, SOUCIE M, NICHOLAS G, WOULFE J, KASSAM A et al., (2013). PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. *Oncotarget* 4: 1266-1279.
- GRIFONI D, GAROIA F, SCHIMANSKI C C, SCHMITZ G, LAURENTI E, GALLE P R, PESSION A, CAVICCHI S and STRAND D (2004). The human protein Hgl-1 substitutes for *Drosophila lethal giant larvae* tumour suppressor function *in vivo*. *Oncogene* 23: 8688-8694.
- GRIFONI D, GAROIA F, BELLOSTAP, PARISI F, DE BIASE D, COLLINA G, STRAND D, CAVICCHI S and PESSION A (2007). aPKCz cortical loading is associated with Lgl cytoplasmic release and tumor growth in *Drosophila* and human epithelia. *Oncogene* 26: 5960-5965.
- GRZESCHIK N A, AMIN N, SECOMBE J, BRUMBY A M and RICHARDSON H E (2007). Abnormalities in cell proliferation and apico-basal cell polarity are separable in *Drosophila lgl* mutant clones in the developing eye. *Dev Biol* 311: 106-123.
- GRZESCHIK N A, PARSONS L, ALLOT M, HARVEY K F and RICHARDSON H E (2010). Lgl, aPKC and Crumbs regulate the Salvador/Warts/Hippo pathway through two distinct mechanisms. *Curr Biol* 20: 573-581.
- HALDER G and JOHNSON R L (2011). Hippo signaling: growth control and beyond. *Development* 130: 9-22.
- HAMARATOGLU F, GAJEWSKI K, SANSORES-GARCIA L, MORRISON C, TAO C and HALDER G (2009). The Hippo tumor-suppressor pathway regulates apical-domain size in parallel to tissue growth. *J Cell Sci* 122: 2351-2359.
- HARIHARAN I K and BILDER D (2006). Regulation of imaginal disc growth by tumor-suppressor genes in *Drosophila*. *Annu Rev Genet* 40: 335-361.
- HUANG J, WU S, BARRERA J, MATTHEWS K, PAN D (2005). The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the *Drosophila* homolog of YAP. *Cell* 122: 421-434.
- HUTTERER A, BETSCHINGER J, PETRONCZKI M and KNOBLICH J A (2006). Sequential roles of Cdc42, Par-6, aPKC, and Lgl in the establishment of epithelial polarity during *Drosophila* embryogenesis. *Dev Cell* 6: 845-854.
- IGAKI T, PASTOR-PAREJA J C, AONUMA H, MIURA M and XU T (2009). Intrinsic tumor suppression and epithelial maintenance by endocytic activation of Eiger/ TNF signaling in *Drosophila*. *Dev Cell* 16: 458-465.
- IGAKI T, PAGLIARINI R A and XU T (2006). Loss of cell polarity drives tumor growth and invasion through JNK activation in *Drosophila*. *Curr Biol* 16: 1139-1146.
- JOHNSTON L A, PROBER DA, EDGAR BA, EISENMAN R N and GALLANT P (1999). *Drosophila myc* regulates cellular growth during development. *Cell* 98: 779-790.
- KALLAY L M, McNICKLE A, BRENNWALD P J, HUBBARD A L and BRAITERMAN L T (2006). Scribble associates with two polarity proteins, Lgl2 and Vanlg2, via distinct molecular domains. *J Cell Biochem* 99: 647-664.
- KHAN S J, BAJPAI A, ALAM M A, GUPTA R P, HARSH S, PANDEY R K, GOEL-BHATTACHARYAS, NIGAMA, MISHRA and SINHA P (2013). Epithelial neoplasia in *Drosophila* entails switch to primitive cell states. *Proc Natl Acad Sci USA* 110: E2163-2172.
- KLEZOVITCH O, FERNANDEZ T E, TAPSCOTT S J and VASIOUKHIN V (2004). Loss of cell polarity causes severe brain dysplasia in *Lgl1* knockout mice. *Genes Dev* 18: 559-571.
- KORSHUNOV A, SYCHEVA R and GOLANOV A (2006). Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). *Acta Neuropathol* 111: 465-474.
- KUPHAL S, WALLNER S, SCHIMANSKI C C, BATAILLE F, HOFER P, STRAND S, STRAND D and BOSSERHOFF A K (2006). Expression of Hgl-1 is strongly reduced in malignant melanoma. *Oncogene* 25: 103-110.
- LEE C Y, ROBINSON K J and DOE C Q (2006). Lgl, Pins and aPKC regulate neuroblast self-renewal versus differentiation. *Nature* 439: 594-598.
- LEE T and LUO L (2001). Mosaic analysis with a repressible cell marker (MARCM) for *Drosophila* neural development. *Trends Neurosci* 24: 251-254.
- LEVYER R and MORENO E (2013). Mechanisms of cell competition: Themes and variations. *JCB* 200: 689-698.
- LI W and BAKER N E (2007). Engulfment is required for cell competition. *Cell* 129: 1215-1225.
- LING C, ZHENG Y, YIN F, YU J, HUANG J, HONG Y, WUS AND PAN D (2010). The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. *Proc Natl Acad Sci USA* 107: 10532-10537.
- LOLOFN, CASAS-TINTÓ S and MORENO E (2012). Cell competition time line: winners kill losers, which are extruded and engulfed by hemocytes. *Cell Rep* 2: 526-539.
- LU X, FENG X, MAN X, YANG G, TANG L, DU D, ZHANG F, YUAN H, HUANG Q, ZHANG Z et al., (2009). Aberrant splicing of Hgl-1 is associated with epatocellular carcinoma progression. *Clin Cancer Res* 15: 3287-3296.
- MCALLISTER S and WEINBERG R A (2010). Tumor-host interactions: a far-reaching relationship. *J Clin Oncol* 28: 4022-4028.
- MENÉNDEZ J, PÉREZ-GARIJO A, CALLEJA M and MORATA G (2010). A tumor-suppressing mechanism in *Drosophila* involving cell competition and the Hippo pathway. *Proc Natl Acad Sci USA* 107: 14651-14656.
- MORATA G and RIPOLL P (1975). *Minutes*: mutants of *Drosophila* autonomously affecting cell division rate. *Dev Biol* 42: 211-221.
- MORENO E, BASLER K and MORATA G (2002). Cells compete for Decapentaplegic survival factor to prevent apoptosis in *Drosophila* wing development. *Nature*

- 416: 755-759.
- MORENO E and BASLER K (2004). dMyc transforms cells into super-competitors. *Cell* 117: 117-129.
- MORENO E (2008). Is cell competition relevant to cancer? *Nat Rev Cancer* 8: 141-147.
- NETO-SILVA R M, DE BECO S and JOHNSTON L A (2010). Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the *Drosophila* homolog of Yap. *Dev Cell* 19: 507-520.
- NORMAN M, WISNIEWSKA K A, LAWRENSEN K, GARCIA-MIRANDA P, TADA M, KAJITAM, MANO H, ISHIKAWAS, IKEGAWAM, SHIMADAT and FUJITAY (2012). Loss of Scribble causes cell competition in mammalian cells. *J Cell Sci* 125: 59-66.
- OERTEL M, MENTHENA A, DABEVA M D and SHAFRITZ D A (2006). Cell competition leads to a high level of normal liver reconstitution by transplanted fetal liver stem/progenitor cells. *Gastroenterology* 130: 507-520.
- OLIVER E R, SAUNDERS T L, TARLÉ S A and GLASER T (2004). Ribosomal protein L24 defect in *belly spot* and *tail* (Bst), a mouse *Minute*. *Development* 131: 3907-3920.
- PAGLIARINI R A and XU T (2003). A genetic screen in *Drosophila* for metastatic behavior. *Science* 302: 1227-1231.
- PIETRAS K and ÖSTMAN A (2010). Hallmarks of cancer: Interactions with the tumor stroma. *Exp Cell Res* 316: 1324-1331.
- PROBER D A and EDGAR B A (2002). Interactions between Ras1, dMyc, and dPI3K signaling in the developing *Drosophila* wing. *Genes Dev* 16: 2286-2299.
- REDDY B V and IRVINE K D (2011). Regulation of *Drosophila* glial cell proliferation by Merlin-Hippo signaling. *Development* 138: 5201-5012.
- REDDY B V and IRVINE K D (2013). Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins. *Dev Cell* 24:459-471.
- REN F, SHI Q, CHEN Y, JIANG A, IP Y T, JIANG H and JIANG J (2013). *Drosophila* Myc integrates multiple signaling pathways to regulate intestinal stem cell proliferation during midgut regeneration. *Cell Res* 23: 1133-1146. doi: 10.1038/cr.2013.101.
- RHINER C and MORENO E (2009). Supercompetition as a possible mechanism to pioneer precancerous fields. *Carcinogenesis* 30: 723-728.
- ROBINSON B S, HUANG J, HONG Y and MÖBERG K H (2010). Crumbs regulates Salvador/Warts/Hippo signaling in *Drosophila* via the FERM-domain protein Expanded. *Curr Biol* 20: 582-590.
- ROLLS M M, ALBERTSON R, SHIH H P, LEE C Y and DOE C Q (2003). *Drosophila* aPKC regulates cell polarity and cell proliferation in neuroblasts and epithelia. *J Cell Biol* 163: 1089-1098.
- RÖPER K (2012). Anisotropy of Crumbs and aPKC drives myosin cable assembly during tube formation. *Dev Cell* 23: 939-953.
- RYOO H D, GORENC T and STELLER H (2004). Apoptotic cells can induce compensatory cell proliferation through the JNK and Wingless signaling pathways. *Dev Cell* 7: 491-501.
- SANCHO M, DI-GREGORIO A, GEORGE N, POZZI S, SÁNCHEZ J M, PERNUTE B and RODRÍGUEZ T A (2013). Competitive interactions eliminate unfit embryonic stem cells at the onset of differentiation. *Dev Cell* 26: 19-30.
- SANSOM O J, MENIEL V S, MUNCAN V, PHESSÉ T J, WILKINS J A, REED K R, VASS J K, ATHINEOS D, CLEVERS H and CLARKE A R (2007). Myc deletion rescues Apc deficiency in the small intestine. *Nature* 446: 676-679.
- SCHIMANSKI C C, SCHMITZ G, KASHYAP A, BOSSERHOFF A K, BATAILLE F, SCHAFFER S C, LEHR H A, BERGER M R, GALLE P R, STRAND S and STRAND D (2005). Reduced expression of Hgl-1, the human homologue of *Drosophila* tumour suppressor gene *lgl*, contributes to progression of colorectal cancer. *Oncogene* 24: 3100-3109.
- SCHROEDER M C and HALDER G (2012). Regulation of the Hippo pathway by cell architecture and mechanical signals. *Semin Cell Dev Biol* 23: 803-811.
- SENOO-MATSUDA N and JOHNSTON L A (2007). Soluble factors mediate competitive and cooperative interactions between cells expressing different levels of *Drosophila* Myc. *Proc Natl Acad Sci USA* 104: 18543-18548.
- SKOULOUDAKI K, PUETZ M, SIMONS M, COURBARD J R, BOEHLKE C, HARTLEBEN B, ENGEL C, MOELLER M J, ENGLERT C, BOLLIG F *et al.*, (2009). Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. *Proc Natl Acad Sci USA*, 106: 8579-8584.
- SUN G and IRVINE K (2011). Regulation of Hippo signaling by Jun kinase signaling during compensatory cell proliferation and regeneration, and in neoplastic tumors. *Dev Biol* 350: 139-151.
- TAKAHASHI K, TANABE K, OHNUKI M, NARITA M, ICHISAKA T, TOMODA K and YAMANAKA S (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861-872.
- TAMORI Y, BIALUCHA C U, TIAN A G, KAJITAM, HUANG Y C, NORMAN M, HARRISON N, POULTON J, IVANOVITCH K, DISCH L *et al.*, (2010). Involvement of Lgl and Mahjong/VprBP in cell competition. *PLoS Biol*: e1000422.
- TERVONEN T A, PARTANEN J I, SAARIKOSKI S T, MYLLYEN M, MARQUES E, PAASONEN K, MOILANENA, WOHLFAHRT G, KOVANEN P E and KLEFSTROM J (2011). Faulty epithelial polarity genes and cancer. *Adv Cancer Res* 111: 98-161.
- TIPPING M and PERRIMON N (2013). *Drosophila* as a model for context-dependent tumorigenesis. *J Cell Physiol* 229: 27-33. doi: 10.1002/jcp.24427.
- THOMAS U, PHANNAVONG B, MULLER B, GARNER C C and GUNDELFINER E D (1997). Functional expression of rat synapse-associated proteins SAP97 and SAP102 in *Drosophila dlg-1* mutants: effects on tumor suppression and synaptic bouton structure. *Mech Dev* 62: 161-174.
- TYLER D M, LI W, ZHUO N, PELLOCK B and BAKER N E (2007). Genes affecting cell competition in *Drosophila*. *Genetics* 175: 643-657.
- VERGHESE S, WAGHMARE I, KWON H, HANES K and KANGO-SINGH M (2012). Scribble acts in the *Drosophila* fat-hippo pathway to regulate warts activity. *PLoS One* 7: e47173.
- WAGNER EF and NEBRED A R (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. *Nat Rev Cancer* 9: 537-549.
- WODARZ A (2005). Molecular control of cell polarity and asymmetric cell division in *Drosophila* neuroblasts. *Curr Opin Cell Biol* 17: 475-481.
- WODARTZ A and NÄTHKE I (2007). Cell polarity in development and cancer. *Nat Cell Biol* 9: 1016-1024.
- WOODHOUSE E, HERSPERGER E, STETLER-STEVENSON W G, LIOTTA L A and SHEARN A (1994). Increased type IV collagenase in *lgl*-induced invasive tumors of *Drosophila*. *Cell Growth Differ* 5: 151-159.
- WOODHOUSE E, HERSPERGER E and SHEARN A (1998). Growth, metastasis, and invasiveness of *Drosophila* tumors caused by mutations in specific tumor suppressor genes. *Dev Genes Evol* 207: 542-550.
- ZIOSI M, BAENA-LÓPEZ L A, GRIFONI D, FROLDI F, PESSION A, GAROIA F, TROTTA V, BELLOSTA P, CAVICCHI S and PESSION A (2010). dMyc functions downstream of Yorkie to promote the supercompetitive behavior of Hippo pathway mutant cells. *PLoS Genet* 6: e1001140.

Further Related Reading, published previously in the *Int. J. Dev. Biol.*

Apoptosis in *Drosophila*: compensatory proliferation and undead cells

Francisco A. Martín, Ainhoa Pérez-Garijo and Ginés Morata
Int. J. Dev. Biol. (2009) 53: 1341-1347

The cellular and genetic bases of organ size and shape in *Drosophila*

Antonio Garcia-Bellido
Int. J. Dev. Biol. (2009) 53: 1291-1303

Cytoskeletal mechanisms responsible for invasive migration of neoplastic cells

Jury M. Vasiliev
Int. J. Dev. Biol. (2004) 48: 425-439
<http://dx.doi.org/10.1387/ijdb.041806jv>

Requirement of *Drosophila* l(2)gl function for survival of the germline cells and organization of the follicle cells in a columnar epithelium during oogenesis.

C De Lorenzo, D Strand and B M Mechler
Int. J. Dev. Biol. (1999) 43: 207-217
<http://dx.doi.org/10.1387/ijdb.10410900>

Tumor suppressor and overgrowth suppressor genes of *Drosophila melanogaster*: developmental aspects

E Gateff
Int. J. Dev. Biol. (1994) 38: 565-590
<http://dx.doi.org/10.1387/ijdb.7779680>

5 yr ISI Impact Factor (2011) = 2.959

